-
Dabei Tang,
Qingyuan Zhang,
Shu Zhao,
Jincai Wang,
Kangping Lu,
Ying Song,
Ling Zhao,
Xinmei Kang, Jingxuan Wang,
Shanqi Xu,
Lantian Tian
[show abstract]
[hide abstract]
ABSTRACT: OBJECTIVES: To investigate the expression profile of miR-1258 and heparanase (HPSE) in breast cancer and to assess their clinicopathological significance. DESIGN AND METHODS: The expression levels of miR-1258 and HPSE were analyzed in normal, benign and malignant breast tissues. Their serum levels were evaluated in healthy women and in patients with benign and malignant breast disease. We studied the correlation between the expression of miR-1258 and HPSE and the clinical features presented by the patients. RESULTS: MiR-1258 was down-regulated and HPSE was up-regulated in breast cancer, with a significant inverse correlation. A reduced miR-1258 expression and an elevated HPSE expression were associated with the lymph node status, late clinical stages, a short overall survival and a short relapse-free survival. In frozen fresh tissue samples, the miR-1258 levels in breast cancer with lymph node metastasis were significantly lower than that of breast cancer without lymph node metastasis and benign disease (BD). In contrast, the HPSE levels in breast cancer with lymph node metastasis were the highest. In serum samples, the miR-1258 levels in metastatic breast cancer (M1) were lower than that of primary breast cancer (M0) and BD. However, serum HPSE levels of M1 patients were significantly higher than that of M0 patients and BD patients. CONCLUSIONS: MiR-1258 may play an important role in breast cancer development and progression by regulating the expression of HPSE, and they might be potential prognostic biomarkers for breast cancer.
Clinical biochemistry 02/2013; · 2.02 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The objectives of this study are to explore the clinical features and treatment outcomes and to investigate the correlation between microvessel density (MVD) and survival in patients with angioimmunoblastic T-cell lymphoma (AITL). We retrospectively analyzed clinical and follow-up data of 31 patients treated in two hospitals during 1995-2009 histologically proven AITL. We also assessed MVD in the lump of 31 previously untreated patients using α-CD34 immunohistochemical staining. The median age of the 31 patients was 48 years, eighty percent of the patients were in an advanced stage. 67.7% of them had B symptoms, with the follow-up of 2-13 years, the 5-year overall survival rate was 25.8%. The response rates (RR) of CHOP group and COP (cyclophosphamide, vincristine and prednisolone) group are 76.5 and 75%, respectively, which is no significant difference (P = 0.894). RR did not differ whether chemotherapy regimens contained anthracycline or not. The 3-year PFS rate for patients who received COP and CHOP regimen was 25.4 and 35.3% (P = 0.562), while 5-year OS rates were 25.0 and 29.4%, respectively (P = 0.667). The median PFS for patients with high MVD and low MVD were 15.1 and 30.0 months (P = 0.048), while the median OS were 20 and 45 months, respectively (P = 0.038). Patients who were sensitive to initial chemotherapy COP regimen have the similar therapeutic effect to CHOP regimen. Patients with high MVD measured in the microenvironment had worse PFS and OS than AITL patients with low expression.
Medical Oncology 10/2011; 29(4):2311-6. · 2.14 Impact Factor
-
Breast Cancer Research and Treatment 07/2011; · 4.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Acquired resistance to doxorubicin has become a serious obstacle in breast cancer treatment. The underlying mechanism responsible for this has not been completely elucidated. In this study, a doxorubicin-resistant MCF-7/Dox cell was developed to mimic the occurrence of acquired doxorubicin resistance. We next contrasted the expression profiles of ICBP90 and Topo IIα and tumor cell growth of different breast cancer cell lines to doxorubicin. Decreased expression levels of ICBP90 and Topo IIα were found in doxorubicin-resistant cells. To examine its function in chemoresistance, RNA interference (RNAi) and forskolin stimulation experiments further demonstrated that ICBP90 and Topo IIα were involved in the proliferation of cells that had acquired doxorubicin resistance. In MCF-7/Dox and ICBP90-siRNA cells, the cell growth wasn't inhibited by doxorubicin and preferentially arrested in G1 phase. However, after forskolin increased the Topo IIα expression, these breast cancer cells were again found to be inhibited by doxorubicin. Further, immunohistochemical assay breast cancer patients accepted EFC regimen showed ICBP90 was significantly associated with tumor cell proliferation, locally advanced disease and Topo IIα expression. In conclusion, down-regulation of ICBP90 induced the descended expression of Topo IIα protein which is the target enzyme of doxorubicin.
European journal of pharmacology 02/2011; 656(1-3):33-8. · 2.59 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The prognostic significance of circulating tumor cells (CTCs) in patients with breast cancer is controversial. We performed a meta-analysis of published literature to assess whether the detection of CTCs in patients diagnosed with primary breast cancer can be used as a prognostic factor. We searched Medline, Science Citation Index, and Embase databases as well as reference lists of relevant articles (including review articles) for studies that assessed the prognostic relevance of tumor cell detection in the peripheral blood (PB). A total of 24 eligible studies with 4,013 cases and 1,333 controls were included. Meta-analyses were performed using a random-effects model, using the hazard ratio (HR) and 95% confidence intervals (95% CIs) as effect measures. The positive detection of CTCs in patients was significantly associated with poor overall survival (OS) (HR = 3.00 [95% CI 2.29-3.94], n = 17, P < 0.0001) and recurrence-free survival (RFS) (HR = 2.67 [95% CI 2.09-3.42], n = 22, P < 0.0001). CTC-positive breast cancers were significantly associated with high histological grade (HR = 1.21 [95% CI 1.09-1.35], n = 34, P < 0.0001), tumor size (>2 cm) (HR = 1.12 [95% CI 1.02-1.22], n = 31, P = 0.01). and nodal status (≥1) (HR = 1.10 [95% CI 1.00-1.21], n = 32, P = 0.037), but cytokeratin-19 (CK-19) mRNA-positive CTCs were not associated with these clinicopathological parameters of breast cancer. Furthermore, the presence of CTCs was not associated with estrogen receptor (ER) negativity, progesterone receptor (PR) negativity, or human epidermal growth factor receptor type 2 (HER2) positivity. Detection of CTCs in the PB indicates poor prognosis in patients with primary breast cancer. Larger clinical studies are required to further evaluate the role of these markers in clinical practice.
Breast Cancer Research and Treatment 02/2011; 130(3):809-16. · 4.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The clinical use of cisplatin, a potent antineoplastic agent, is limited by its severe adverse effects. The present study was designed to evaluate the effects of resveratrol on cisplatin-induced cardiac injury. Resveratrol is a potent free radical scavenger. In the present study, we tested whether resveratrol would prevent cisplatin-induced cardiotoxicity in rats. Plasma-enzyme activities and histologic myocardial changes were examined. The anticancer role of resveratrol and/or cisplatin were measured by MTT. Our data showed that cisplatin led to cardiac-function deterioration, myocardial injury, increased lactate dehydrogenase, creatine kinase, malondialdehyde activities, and decreased activities of superoxide dismutase, glutathione, glutathione peroxidase, and catalase. Treatment with resveratrol effectively hindered the adverse effects of cisplatin in a dose-dependent manner, such as myocardial injury and impaired heart function. An in vitro cytotoxic study showed that resveratrol could increase the antineoplastic activity of cisplatin to A549 adenocarcinoma cells. All the above lines of evidence suggest that resveratrol protects cardiomyocytes from cisplatin-induced cardiotoxicity via the suppression of oxidative stress.
Cancer Biotherapy & Radiopharmaceuticals 12/2009; 24(6):675-80. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of this study was to evaluate the effect of combining dacarbazine (DTIC) and granulocyte/macrophage colony-stimulating factor (GM-CSF) with interleukin-2 (IL-2) in patients with advanced malignant melanoma.
Twenty-seven (27) patients with advanced malignant melanoma received dacarbazine (500 mg/m(2)/days 1-2, intravenously), GM-CSF (175 ug/m(2)/days 3-6, subcutaneously), and interleukin-2 (400 MIU/m(2)/days 7-10, subcutaneously). Each treatment cycle required 21 days to completion.
Time to progression was 7-11 months. The total effective rate was 44.4%, and the combination of chemotherapy, GM-CSF, and IL-2 had low toxicity.
The combination of DTIC with GM-CSF and IL-2 is feasible and possibly efficacious for clinical use.
Cancer Biotherapy & Radiopharmaceuticals 05/2009; 24(2):237-41. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. DLBCL is a highly variable tumor, with different responses to therapy. The aim of this study is to explore the association between immunophenotype and treatment response.
We analyzed the expression of Bcl-6, CD10, and MUM1 in 130 cases of DLBCL using immunohistochemistry. The cases were subdivided into germinal center B-cell-like (GCB) and non-GCB subtypes, and were randomly assigned to receive either 6-8 cycles of CHOP every 2 weeks or standard CHOP every 3 weeks.
After a median followup duration of 40 months, 3-year overall survival of biweekly CHOP was better than standard CHOP in the non-GCB group (58.3 vs. 38.6%, p < 0.05). However, the therapeutic effect of biweekly CHOP and standard CHOP was not different in the GCB group (64.8 vs. 57.5%, p > 0.05).
Immunohistochemistry analysis of different subgroups is useful to find the suitable therapy. Biweekly CHOP showed higher efficacy than standard treatment in the non-GCB subgroup.
Onkologie 01/2009; 32(12):719-23. · 0.87 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Capecitabine is a novel fluoropyrimidine carbamate, which has a broader spectrum of antitumor activity than other fluoropyrimidines, such as 5-FU, DFUR, or UFT; it has proved effective over a wide dose range. Recent research has suggested that frequent administration of lower doses of certain chemotherapeutic drugs might enhance their antiangiogenic effect. The present study investigated the antiangiogenic effect of capecitabine on breast cancer. In order to augment its efficacy, we combined capecitabine chemotherapy with ginsenoside Rg3. Our results indicate that a metronomic regimen of capecitabine inhibited angiogenesis in breast cancer, and its antiangiogenic effects may be further enhanced by the concurrent administration of ginsenoside Rg3. As an antiangiogenic method, this regimen presented better antitumor effects, less toxicity, and reduced susceptibility to drug resistance.
Cancer Biotherapy & Radiopharmaceuticals 11/2008; 23(5):647-53. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Natural medicines derived from plants are drawing more and more interest in the prevention and treatment of diseases because of their unique characteristics, which include having fewer adverse effects and being more suitable for long-term use compared with synthesized chemicals. To explore the potentially health-promoting role of genistein, we used a rat model of rheumatoid arthritis (RA) induced by a subplantar injection of collagen.
In collagen-induced rheumatoid arthritis (CIA) rat model, their immunomodulatory activity on rat peripheral blood mononuclear cells (PBMC) was evaluated. Lymphocyte transformation was evaluated by MTT immunoassay, secretion of interferon-gamma (IFN-gamma) and interleukin 4 (IL-4) by enzyme-linked immunosorbent assay (ELISA), and expression of T-bet and GATA-3 by PCR.
The results showed that genistein modulated a Th1-predominant immune response because they significantly suppressed the secretion of IFN-gamma and augmented the IL-4 production, showed its immune modulation role of keeping the Th1/Th2 balance.
Accordingly, genistein could play a role in reducing RA-induced inflammation and affecting the immune system in powerful ways.
Maturitas 05/2008; 59(4):405-12. · 2.77 Impact Factor
